Effects of omeprazole in improving concurrent chemoradiotherapy efficacy in rectal cancer

Table 5 Univariate Cox analysis of the impact of various characteristics on patient survival

Characteristics	DFS		P value	OS		P value
	HR	95%CI		HR	95%CI
Sex
Male vs Female	0.91	0.42-1.65	0.800	0.93	0.41-2.09	0.860
Age (yr)
< 60 vs ≥ 60	0.80	0.40-1.62	0.530	1.05	0.50-2.19	0.910
BMI
< 25 vs ≥ 25	0.22	0.05-0.93	0.039	0.26	0.06-1.11	0.069
Tumor size (cm)
≤ 3 vs > 3	1.23	0.60-2.51	0.570	0.98	0.46-2.08	0.960
Tumor grade
1 vs 2, 3	1.08	0.47-2.50	0.850	0.96	0.41-2.26	0.930
cTNM
II vs III	2.23	0.92-5.41	0.075	1.96	0.80-4.80	0.144
CEA (ng/mL)
< 5 vs ≥ 5	0.91	0.46-1.81	0.790	0.72	0.34-1.51	0.390
CA199 (U/mL)
< 35 vs ≥ 35	1.77	0.77-4.08	0.180	1.30	0.50-3.40	0.600
CRT efficacy
Poor vs good	0.43	0.19-0.95	0.036	0.55	0.24-1.24	0.150
ypTNM
ypcr, I,II vs III	1.61	1.14-2.27	0.006	1.46	1.01-2.11	0.045
Adjuvant CT
Non vs yes	0.69	0.30-1.60	0.390	0.60	0.25-1.40	0.240
EOU
Non vs yes	1.17	0.59-2.31	0.660	1.13	0.54-2.37	0.750
EOG
Non vs yes	0.30	0.90-0.97	0.044	0.37	0.11-1.23	0.110

EOU: Eligible OME users; Non-EOU: Non-eligible OME users; EOG: Effective OME group; Non-EOG: Non-effective OME group; BMI: Body mass index; Adjuvant CT: Adjuvant chemotherapy.